WASHINGTON, D.C. — Lady A’s co‑lead vocalist Charles Kelley announced Tuesday that he has been diagnosed with multiple myeloma, a rare blood cancer that accounts for roughly 1 % of all cancers in the United States.

In an Instagram video captioned “A little health update,” Kelley said, “Hey everybody. Just wanted to give a quick update on some health stuff – I’ve been diagnosed with multiple myeloma.” He added, “I’m confident that we’re going to get through it,” and thanked fans for their support. Multiple myeloma affects about 34,000 new patients annually in the U.S., most of whom are over 65.

KEY POINTIn an Instagram video captioned “A little health update,” Kelley said, “Hey everybody.

Medical experts note that the disease is characterized by malignant plasma cells that accumulate in bone marrow, leading to bone lesions, anemia and kidney dysfunction. The FDA currently lists 12 approved regimens, including daratumumab‑based combinations and CAR‑T cell therapy, which have extended median overall survival from 3.5 years in 2000 to 5.8 years in recent trials. Dr. Elena Ramirez, a hematologist at Johns Hopkins, said, “Early detection and modern triplet therapy can achieve deep responses in up to 70 % of patients.”

For Kelley, the diagnosis means a treatment plan that may involve an induction regimen, followed by autologous stem‑cell transplantation and maintenance therapy. He has indicated plans to continue touring when medically cleared, and his management has launched a GoFundMe that has raised over $150,000 to offset medication costs and travel for specialist appointments.

Advocacy groups stress that the rarity of multiple myeloma hampers large‑scale research, yet recent phase‑III trials suggest that bispecific antibodies could improve response rates to 85 % within a year. “Patients benefit when clinical data translate quickly into practice,” said Dr. Ramirez, noting that the FDA’s accelerated approval pathway has shortened the gap between trial results and patient access.

Key Takeaways

• Multiple myeloma represents about 1 % of U.S. cancers, with an annual incidence of roughly 34,000 cases.
• The FDA currently approves 12 therapeutic regimens, including CAR‑T and bispecific antibodies, boosting median survival to nearly six years.
• Patient advocacy and fundraising play a crucial role in covering high‑cost treatments and supporting clinical trial enrollment.

While Kelley’s public disclosure underscores the personal toll of a rare cancer, it also highlights advances in therapy that are reshaping outcomes for thousands of patients nationwide.